Dafinchi AI

MRVI

Healthcare

Adjusted EBITDA was negative $10.4 million in Q2 2025 versus positive $13 million in Q2 2024.
Basic and diluted EPS loss was $0.27 per share compared to $0.07 loss in Q2 2024; adjusted EPS loss was $0.08 versus $0.01 loss in prior year.
BST segment revenue grew 10% year-over-year to $16.3 million with an adjusted EBITDA margin of 67%.
Cash balance ended at $270 million with $297 million in long-term debt; cash used in operations was $10.3 million.
GAAP net loss was $69.8 million in Q2 2025 compared to $18.4 million loss in Q2 2024.
NAP segment revenue was $31.1 million with a 3% year-over-year increase in base business, showing sequential growth from Q1 2025.
Q2 2025 revenue was $47.4 million, down from $69.4 million in Q2 2024, but base revenue excluding high-volume CleanCap increased by 5%.

MDGL

Healthcare

Madrigal Pharmaceuticals reported net sales of $212.8 million in Q2 2025, a 55% increase quarter-over-quarter.
R&D expenses decreased to $54.1 million from $71.1 million year-over-year due to lower clinical trial costs.
SG&A expenses increased to $196.9 million from $105.4 million year-over-year, driven by commercial launch activities.
The company ended Q2 2025 with $802 million in cash and equivalents and secured a $500 million senior secured credit facility.
U.S. Rezdiffra net sales are annualizing at over $800 million.

Earnings Feed